There are 2137 resources available
LBA3_PR - An international randomized trial, comparing post-operative conformal radiotherapy (PORT) to no PORT, in patients with completely resected non-small cell lung cancer (NSCLC) and mediastinal N2 involvement: Primary end-point analysis of LungART (IFCT-0503, UK NCRI, SAKK) NCT00410683
Presenter: Cécile Le Pechoux
Session: Presidential Symposium II
Resources:
Abstract
Slides
Webcast
LBA4 - IPATential150: Phase III study of ipatasertib (ipat) plus abiraterone (abi) vs placebo (pbo) plus abi in metastatic castration-resistant prostate cancer (mCRPC)
Presenter: Johann de Bono
Session: Presidential Symposium II
Resources:
Abstract
Slides
Webcast
610O - Final overall survival (OS) analysis of PROfound: Olaparib vs physician’s choice of enzalutamide or abiraterone in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations
Presenter: Johann de Bono
Session: Presidential Symposium II
Resources:
Abstract
Slides
Webcast
LBA5_PR - Abemaciclib in high risk early breast cancer
Presenter: Stephen Johnston
Session: Presidential Symposium II
Resources:
Abstract
Slides
Webcast
CN24 - Sexual function in young adults following a brain tumour diagnosis
Presenter: Charlotta Bergstrom
Session: EONS13: Age specific care: Adolescents and young adults (AYA)
Resources:
Abstract
Slides
Webcast
274O - Health-related quality of life (HRQoL) changes with veliparib in patients (pts) with metastatic or locally advanced breast cancer in the phase III BROCADE 3 study
Presenter: Michael Friedlander
Session: Proffered Paper - Breast cancer, metastatic 2
Resources:
Abstract
Slides
Webcast
275O - Impact of tucatinib on health-related quality of life (HRQoL) in patients with HER2+ metastatic breast cancer (MBC) with and without brain metastases (BM)
Presenter: Volkmar Mueller
Session: Proffered Paper - Breast cancer, metastatic 2
Resources:
Abstract
Slides
Webcast
276O - Pooled analysis of patient (pt)-reported quality of life (QOL) in the MONALEESA (ML)-2, -3, and -7 trials of ribociclib (RIB) plus endocrine therapy (ET) to treat hormone receptor–positive, HER2-negative (HR+/HER2−) advanced breast cancer (ABC)
Presenter: Peter A. Fasching
Session: Proffered Paper - Breast cancer, metastatic 2
Resources:
Abstract
Slides
Webcast
LBA19 - GEICAM/2014-12 (FLIPPER) study: First analysis from a randomized phase II trial of fulvestrant (F)/palbociclib (P) versus (vs) F/placebo (PL) as first-line therapy in postmenopausal women with HR (hormone receptor)+/HER2– endocrine sensitive advanced breast cancer (ABC)
Presenter: Joan Albanell
Session: Proffered Paper - Breast cancer, metastatic 2
Resources:
Abstract
Slides
Webcast
LBA87 - A pragmatic cluster-randomized trial of ambulatory toxicity management in patients receiving adjuvant or neo-adjuvant chemotherapy for early stage breast cancer (AToM)
Presenter: Monika Krzyzanowska
Session: Proffered Paper - Supportive and palliative care
Resources:
Abstract
Slides
Webcast